A Randomized Placebo-Controlled Trial of Sarilumab in Hospitalized Patients with Covid-19
ABSTRACT BACKGROUND Sarilumab (anti-interleukin-6 receptor-α monoclonal antibody) may attenuate the inflammatory response in Covid-19.METHODS We performed an adaptive, phase 2/3, randomized, double-blind, placebo-controlled trial of intravenous sarilumab 200 mg or 400 mg in adults hospitalized with Covid-19. The phase 3 primary analysis population (cohort 1) was patients with critical Covid-19 receiving mechanical ventilation (MV) randomized to sarilumab 400 mg or placebo. The primary end point for phase 3 was the proportion of patients with ≥1-point improvement in clinical status from baseline to day 22.RESULTS Four-hundred fifty-seven (457) and 1365 patients were randomized and treated in phases 2 and 3, respectively. Among phase 3 critical patients receiving MV (n=289; 34.3% on corticosteroids), the proportion with ≥1-point improvement in clinical status (alive not receiving MV) at day 22 was 43.2% in sarilumab 400 mg and 35.5% in placebo (risk difference [RD] +7.5%; 95% confidence interval [CI], –7.4 to 21.3; P=0.3261), representing a relative risk improvement of 21.7%. Day 29 all-cause mortality was 36.4% in sarilumab 400 mg versus 41.9% in placebo (RD –5.5%; 95% CI, –20.2 to 8.7; relative risk reduction 13.3%). In post hoc analyses pooling phase 2 and 3 critical patients receiving MV, the hazard ratio (HR) for death in sarilumab 400 mg compared with placebo was 0.76 (95% CI, 0.51 to 1.13) overall, improving to 0.49 (95% CI, 0.25 to 0.94) in patients receiving corticosteroids at baseline.CONCLUSION In hospitalized patients with Covid-19 receiving MV, numerical benefits with sarilumab did not achieve statistical significance, but benefit may be greater in patients receiving corticosteroids. A larger study is required to confirm this observed numerical benefit.(<jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</jats:ext-link> number, <jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="clintrialgov" xlink:href="NCT04315298">NCT04315298</jats:ext-link>).
Medienart: |
Preprint |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
bioRxiv.org - (2021) vom: 30. Okt. Zur Gesamtaufnahme - year:2021 |
---|
Sprache: |
Englisch |
---|
Links: |
Volltext [kostenfrei] |
---|
doi: |
10.1101/2021.05.13.21256973 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
XBI020560206 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | XBI020560206 | ||
003 | DE-627 | ||
005 | 20230429090245.0 | ||
007 | cr uuu---uuuuu | ||
008 | 210517s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1101/2021.05.13.21256973 |2 doi | |
035 | |a (DE-627)XBI020560206 | ||
035 | |a (biorXiv)10.1101/2021.05.13.21256973 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | |a 570 |q DE-84 | |
100 | 1 | |a Sivapalasingam, Sumathi |e verfasserin |4 aut | |
245 | 1 | 0 | |a A Randomized Placebo-Controlled Trial of Sarilumab in Hospitalized Patients with Covid-19 |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a ABSTRACT BACKGROUND Sarilumab (anti-interleukin-6 receptor-α monoclonal antibody) may attenuate the inflammatory response in Covid-19.METHODS We performed an adaptive, phase 2/3, randomized, double-blind, placebo-controlled trial of intravenous sarilumab 200 mg or 400 mg in adults hospitalized with Covid-19. The phase 3 primary analysis population (cohort 1) was patients with critical Covid-19 receiving mechanical ventilation (MV) randomized to sarilumab 400 mg or placebo. The primary end point for phase 3 was the proportion of patients with ≥1-point improvement in clinical status from baseline to day 22.RESULTS Four-hundred fifty-seven (457) and 1365 patients were randomized and treated in phases 2 and 3, respectively. Among phase 3 critical patients receiving MV (n=289; 34.3% on corticosteroids), the proportion with ≥1-point improvement in clinical status (alive not receiving MV) at day 22 was 43.2% in sarilumab 400 mg and 35.5% in placebo (risk difference [RD] +7.5%; 95% confidence interval [CI], –7.4 to 21.3; P=0.3261), representing a relative risk improvement of 21.7%. Day 29 all-cause mortality was 36.4% in sarilumab 400 mg versus 41.9% in placebo (RD –5.5%; 95% CI, –20.2 to 8.7; relative risk reduction 13.3%). In post hoc analyses pooling phase 2 and 3 critical patients receiving MV, the hazard ratio (HR) for death in sarilumab 400 mg compared with placebo was 0.76 (95% CI, 0.51 to 1.13) overall, improving to 0.49 (95% CI, 0.25 to 0.94) in patients receiving corticosteroids at baseline.CONCLUSION In hospitalized patients with Covid-19 receiving MV, numerical benefits with sarilumab did not achieve statistical significance, but benefit may be greater in patients receiving corticosteroids. A larger study is required to confirm this observed numerical benefit.(<jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</jats:ext-link> number, <jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="clintrialgov" xlink:href="NCT04315298">NCT04315298</jats:ext-link>) | ||
700 | 1 | |a Lederer, David J. |e verfasserin |4 aut | |
700 | 1 | |a Bhore, Rafia |e verfasserin |4 aut | |
700 | 1 | |a Hajizadeh, Negin |e verfasserin |4 aut | |
700 | 1 | |a Criner, Gerard |e verfasserin |4 aut | |
700 | 1 | |a Hosain, Romana |e verfasserin |4 aut | |
700 | 1 | |a Mahmood, Adnan |e verfasserin |4 aut | |
700 | 1 | |a Giannelou, Angeliki |e verfasserin |4 aut | |
700 | 1 | |a Somersan-Karakaya, Selin |e verfasserin |4 aut | |
700 | 1 | |a O’Brien, Meagan |e verfasserin |4 aut | |
700 | 1 | |a Boyapati, Anita |e verfasserin |4 aut | |
700 | 1 | |a Parrino, Janie |e verfasserin |4 aut | |
700 | 1 | |a Musser, Bret |e verfasserin |4 aut | |
700 | 1 | |a Labriola-Tompkins, Emily |e verfasserin |4 aut | |
700 | 1 | |a Ramesh, Divya |e verfasserin |4 aut | |
700 | 1 | |a Purcell, Lisa A. |e verfasserin |4 aut | |
700 | 1 | |a Gulabani, Daya |e verfasserin |4 aut | |
700 | 1 | |a Kampman, Wendy |e verfasserin |4 aut | |
700 | 1 | |a Waldron, Alpana |e verfasserin |4 aut | |
700 | 1 | |a Gong, Michelle Ng |e verfasserin |4 aut | |
700 | 1 | |a Saggar, Suraj |e verfasserin |4 aut | |
700 | 1 | |a Sperber, Steven J. |e verfasserin |4 aut | |
700 | 1 | |a Menon, Vidya |e verfasserin |4 aut | |
700 | 1 | |a Stein, David K. |e verfasserin |4 aut | |
700 | 1 | |a Sobieszczyk, Magdalena E. |e verfasserin |4 aut | |
700 | 1 | |a Park, William |e verfasserin |4 aut | |
700 | 1 | |a Aberg, Judith A. |e verfasserin |4 aut | |
700 | 1 | |a Brown, Samuel M. |e verfasserin |4 aut | |
700 | 1 | |a Kosmicki, Jack A. |e verfasserin |4 aut | |
700 | 1 | |a Horowitz, Julie E. |e verfasserin |4 aut | |
700 | 1 | |a Ferreira, Manuel A. |e verfasserin |4 aut | |
700 | 1 | |a Baras, Aris |e verfasserin |4 aut | |
700 | 1 | |a Kowal, Bari |e verfasserin |4 aut | |
700 | 1 | |a DiCioccio, A. Thomas |e verfasserin |4 aut | |
700 | 1 | |a Akinlade, Bolanle |e verfasserin |4 aut | |
700 | 1 | |a Nivens, Michael C. |e verfasserin |4 aut | |
700 | 1 | |a Braunstein, Ned |e verfasserin |4 aut | |
700 | 1 | |a Herman, Gary |e verfasserin |4 aut | |
700 | 1 | |a Yancopoulos, George D. |e verfasserin |4 aut | |
700 | 1 | |a Weinreich, David M. |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2021) vom: 30. Okt. |
773 | 1 | 8 | |g year:2021 |g day:30 |g month:10 |
856 | 4 | 0 | |u http://dx.doi.org/10.1101/2021.05.13.21256973 |z kostenfrei |3 Volltext |
912 | |a GBV_XBI | ||
912 | |a SSG-OLC-PHA | ||
951 | |a AR | ||
952 | |j 2021 |b 30 |c 10 | ||
953 | |2 045F |a 570 |